Dr. Reddy’s Laboratories is currently trading at Rs. 4505.15, up by 0.90 points or 0.02% from its previous closing of Rs. 4504.25 on the BSE.
The scrip opened at Rs. 4559.00 and has touched a high and low of Rs. 4559.00 and Rs. 4494.40 respectively. So far 47881 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 5 has touched a 52 week high of Rs. 4754.30 on 10-Aug-2020 and a 52 week low of Rs. 2490.30 on 21-Aug-2019.
Last one week high and low of the scrip stood at Rs. 4590.30 and Rs. 4438.20 respectively. The current market cap of the company is Rs. 74857.97 crore.
The promoters holding in the company stood at 26.74%, while Institutions and Non-Institutions held 43.97% and 15.25% respectively.
Dr. Reddy’s Laboratories has launched Avigan (Favipiravir) 200 mg Tablets in India. The launch is part of the global licensing agreement with Fujifilm Toyama Chemical Co. that grants Dr. Reddy’s the exclusive rights to manufacture, sell and distribute Avigan (Favipiravir) 200 mg Tablets in India.
Avigan (Favipiravir) has been approved by the Drugs Controller General of India (DCGI) for the treatment of patients with mild to moderate COVID-19 disease. Dr. Reddy’s Avigan comes in a complete therapy pack of 122 tablets with a two-year shelf life.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.